FDA Approves Inavolisib with Palbociclib and Fulvestrant for Advanced Breast Cancer
On October 10, 2024, the FDA approved Inavolisib in combination with Palbociclib and Fulvestrant for adults with advanced, endocrine-resistant, HR-positive, HER2-negative breast cancer with PIK3CA mutations.
Read MoreFDA approval means that a drug or medical treatment has been carefully tested and proven to be safe and effective for people to use. The U.S. Food and Drug Administration (FDA) gives this approval after looking at data from clinical trials.
These trials are research studies with human participants that test how well a new treatment works and what side effects it may have. Clinical trials happen in different stages and provide the important information the FDA needs to make sure a product is safe and meets quality standards before it can be sold to the public.
Categories
- Erectile Dysfunction
- FDA Approval and Clinical Trials
- Generic Drugs
- Medicine Import Guidelines
- Premature Ejaculation
Recent Blog
- FDA Approves Inavolisib with Palbociclib and Fulvestrant for Advanced Breast Cancer
15, Oct 2024 - Premature Ejaculation Unveiled: Symptoms, Causes, and Treatments
13, Aug 2024 - Beyond Weight Loss: The Multifaceted Impact of GLP-1 Drugs
23, Jul 2024 - Comparing Sildenafil, Tadalafil, and Vardenafil: Which One Should You Choose?
23, Jul 2024 - Top 10 Best ED Pills to Consider Today
03, Jul 2024
